Chinook Therapeutics Inc
40.295 - 40.51
0 - 40.51
Join Discuss about KDNY with like-minded investors
New option listings for October 6th include Chinook Therapeutics Inc (KDNY) and Palantir Technologies Inc (PLTR) (Class A Stock) (PLTR). Option delistings effective October 6th include Aduro Biotech Inc ( ADRO) , TD Ameritrade Holding Corporation ( AMTD) , and Noble Energy Inc (NBL).
146 Replies 11 👍 12 🔥
Next Dividend Date
chinook therapeutics (nasdaq: kdny) is a clinical-stage biotechnology company developing precision medicines for kidney diseases. kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems. drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
CEO: Stephen Isaacs
HQ: 740 Heinz Ave Berkeley, 94710-2748 California